Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. [PDF]
Am J Cardiovasc Drugs, 2016 Sohn IS +7 more
europepmc +1 more source
A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval. [PDF]
J Clin Pharmacol, 2016 Mendell J +3 more
europepmc +1 more source
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control [PDF]
, 2012 Bobby V. Khan, Nadya Merchant
core +2 more sources
A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil. [PDF]
Sci Pharm, 2015 Hanumantha Rao B +5 more
europepmc +1 more source
Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis. [PDF]
Drug Des Devel Ther, 2015 Sievers P +7 more
europepmc +1 more source
Olmesartan-Associated Enteropathy With Severe Diarrhoea and Acute Kidney Injury. [PDF]
CureusNikolaeva A, Della Vecchia A.
europepmc +1 more source
Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology. [PDF]
Saudi Pharm J, 2016 Attari Z +3 more
europepmc +1 more source
Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats. [PDF]
Biomed Rep, 2014 Si X +5 more
europepmc +1 more source